

Clinical Trial Protocol

Iranian Registry of Clinical Trials

30 Jul 2026

Clinical trial to evaluate the resectability rate and tumor response to neoadjuvant chemo radiotherapy in patients with locally advanced proximal gastric cancer and esophagogastric cancer.

Protocol summary

Summary

The aim of the study: Evaluation of resectability rate and tumor response to neoadjuvant chemo radiotherapy in patients with locally advanced proximal gastric cancer and esophagogastric cancer Study design: Clinical trial Study population: Patients with locally advanced proximal gastric cancer and esophagogastric cancer referred to Omid hospital of Mashhad. Inclusion criteria: All patients with locally advanced proximal gastric cancer and esophagogastric cancer who have positive biopsy results and has been filled the consent form informally. Exclusion criteria: Patients (illness) at stage I,IV - patient dissatisfaction- comorbid diseases that prevent oncologic treatment- previous cancer- previous chemotherapy or radiotherapy- hepatic and renal dysfunction that prevents oncologic treatments- Performance status 3,4 ECOG Intervention : All patients with locally advanced proximal gastric cancer and esophagogastric cancer that have positive biopsy result are considered for receiving chemo radiation therapy before surgery. Before treatment, patients undergo a complete evaluation of metastatic spread. Measurements before treatment include: a full clinical examination, endoscopy and biopsy, endosonography, abdominal CT scan, chest radiography, complete blood tests including CBC, liver and renal function test. After criteria approval, eligible patients entered Preoperative Chemo radiation trial. Therapeutic regimen including: chemotherapy and radiation with capecitabin 625 mg/m²/bid as otherwise afford , 5 - fluorouracil 325 mg/m² and leucovorin 20/mg² at the first four days and the last three days of radiotherapy . Radiotherapy with a total dose of 4500 cgy with two fields AP-PA and with a fractions of 180 - 200 cgy done. During third to fourth week of treatment, blood test (CBC) is controlled (to control hematologic side effects) and also controlled before surgery. 4 - 6 weeks after completing Chemo radiation, patients are

referred for surgery. After surgery, specimens are evaluated for pathologic response and resectability. The postoperative morbidity and mortality includes leakage is investigated.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2014072015044N1**

Registration date: **2014-07-20, 1393/04/29**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2014-07-20, 1393/04/29

Registrant information

Name

Soodabeh Shahidsales

Name of organization / entity

Cancer research center

Country

Iran (Islamic Republic of)

Phone

+98 51 1846 1518

Email address

shahidsaless@mums.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research, Mashhad University of Medical Sciences.

Expected recruitment start date

2012-03-20, 1391/01/01

Expected recruitment end date

2014-12-21, 1393/09/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Clinical trial to evaluate the resectability rate and tumor response to neoadjuvant chemo radiotherapy in patients with locally advanced proximal gastric cancer and esophagogastric cancer.
Public title
Neoadjuvant chemoradiotherapy in patients with locally advanced gastric cancer
Purpose
Treatment
Inclusion/Exclusion criteria
The main inclusion criteria: All patients with locally advanced proximal gastric cancer and esophagogastric cancer who have positive biopsy results and has been filled the consent form informally. The main exclusion criteria: patients (illness) at stage I and IV; patient dissatisfaction; comorbid diseases that prevent oncologic treatment; previous cancer; previous chemotherapy or radiotherapy; hepatic and renal dysfunction that prevents oncologic treatments; Performance status 3,4 ECOG
Age
No age limit
Gender
Both
Phase
2
Groups that have been masked
No information
Sample size
Target sample size: 30
Randomization (investigator's opinion)
N/A
Randomization description
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Single
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee

Ethics committee of Mashhad University of Medical Sciences
Street address
Daneshgah st., Ghoreschi Building
City
Mashhad
Postal code
Approval date
2012-02-18, 1390/11/29
Ethics committee reference number
1

Health conditions studied

1

Description of health condition studied
Proximal gastric cancer
ICD-10 code
C16.1
ICD-10 code description
Fundus of stomach

2

Description of health condition studied
Gastro-oesophageal cancer
ICD-10 code
C16.0
ICD-10 code description
Gastro-oesophagea cancerl

Primary outcomes

1

Description
Evaluation of resectability rate and tumor response in patients with locally advanced proximal gastric cancer and esophagogastric cancer treated with neoadjuvant chemoradiotherapy
Timepoint
Pathologic Evaluation of surgical specimen
Method of measurement
Pathologic response

Secondary outcomes

1

Description
Rate of surgical complication
Timepoint
Post operation
Method of measurement
Incisional leek,post op mortality

Intervention groups

1

Description

All patients with locally advanced proximal gastric cancer and junction esophagogastric cancer receive Preoperative Chemoradiation therapy before surgery are candidates with a positive biopsy . Before treatment , patients underwent a complete evaluation of metastatic spread , and are to be excluded . Measures before treatment included a full clinical examination , endoscopy and biopsy , Endosonography , abdominal CT , chest radiography , complete blood tests including CBC , liver and renal function test . After approval criteria , and the patients entered Trial Preoperative Chemoradiation placed. Drug regimens , including chemotherapy and radiation Capecitabin 625 mg/m2/Bid as otherwise afford , 5 - fluorouracil 325 mg/m2 and locoverin 20 mg /m2 of 4 first days and 3 last days of radiotherapy . Radiotherapy with a total dose of 4500 cgy with two field AP-PA with fractions 180 - 200 cgy done . Third to fourth week of treatment, blood tests (CBC) is controlled (to control hematologic effects) controlled blood testing before surgery . 4 -6 weeks after Chemoradiation patient is referred for surgery . After surgical pathology specimens of pathologic response and resection of the features represented. The morbidity and mortality of postoperative incisional surgery includes Leak is investigated.

Category

Treatment - Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Mashhad Omid Hospital

Full name of responsible person

Soodabeh Shahidsales

Street address

Omid Hospital, Koohsangi st. , Mashhad

City

Mashhad

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research, Mashhad University of Medical Sciences

Full name of responsible person

Zohreh Boostanian

Street address

Vice chancellor for research, Office building Qureshi, University st., Mashhad

City

Mashhad

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice chancellor for research, Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Omid Hospital

Full name of responsible person

Ali Emadi Torghabeh

Position

Assistant of radiation oncology

Other areas of specialty/work

Street address

Omid Hospital, Koohsangi st., Mashhad, Iran

City

Mashhad

Postal code

Phone

+98 51 1846 1518

Fax

Email

emadita1@mums.ac.ir

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Cancer research center , Faculty of medicine, Mashhad University of Medical Sciences

Full name of responsible person

Soodabeh Shahidsales

Position

Assistant Professor of Radiation Oncology

Other areas of specialty/work

Street address

Cancer Research Center, Omid Hospital, Koohsangi st., Mashhad, Iran

City

Mashhad

Postal code

Phone

+98 51 1846 1518

Fax

Email

shahidsaless@mums.ac.ir

Web page address

<http://www.mums.ac.ir/cancer>

Fax

Email

emadital1@mums.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Mashhad University OF Medical Sciences

Full name of responsible person

Ali Emadi Torghabeh

Position

Assistant

Other areas of specialty/work

Street address

Omid Hospital, Koohsangi st., Mashhad, Iran

City

Mashhad

Postal code

Phone

+98 51 1854 6084

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty